Search for Clinical Trial Results

Sponsored By

Leukemia, Myeloid, Accelerated Phase - 12 Studies Found

Status Study
Completed Study Name: Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia
Condition: Chronic Myelogenous Leukemia
Date: 2005-01-12
Interventions: Drug: Dasatinib Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, sw
Completed Study Name: STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Date: 2000-07-05
Interventions: Drug: imatinib mesylate
Completed Study Name: Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
Condition: Leukemia
Date: 2005-05-03
Interventions:
  • Biological: recombinant interferon alfa
  • Bi
Terminated Study Name: Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Myeloid Leukemia
Date: 2009-05-06
Interventions: Drug: Dasatinib (Sprycel) 100mg of Dasatinib will be administered as tablets, by mouth, once a day (or t
Withdrawn Study Name: Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Condition: Leukemia, Myeloid, Chronic
Date: 2008-08-07
Interventions: Biological: Ipilimumab IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three
Recruiting Study Name: A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Condition: Chronic Myeloid Leukemia
Date: 2014-02-28
Interventions: Drug: Omacetaxine mepesuccinate 3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of t
Terminated Study Name: Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate
Condition:
  • Accelerated Phase Chronic Myelogenous Leukemia
  • Chronic Myelogen
    Date: 2011-08-30
    Interventions:
    • Drug: dasatinib Given PO
Completed Study Name: Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
Condition:
  • Accelerated Phase Chronic Myelogenous Leukemia
  • Blastic Phase Ch
    Date: 2003-02-05
    Interventions:
    • Drug: imatinib mesylate Given

Terminated Study Name: Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Condition:
  • Accelerated Phase Chronic Myelogenous Leukemia
  • Blastic Phase Ch
    Date: 2005-01-07
    Interventions:
    • Drug: imatinib mesylate Given

Recruiting Study Name: Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Condition:
  • Chronic Phase Chronic Myeloid Leukemia
  • Accelerated Phase Chronic Myelo
    Date: 2013-07-28
    Interventions:
    • Drug: Nilotinib Nilotinib dose
Next >>>